A secret that hides Teva- Pharmaceutical Industries Ltd. ADR’s strength (NYSE:TEVA)

Stocks of Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) traded higher last session on Wall Street, down -1.03% to $8.68.

According to the data, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) has 12 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $8.00, we find $10.00. Given the previous closing price of $8.77, this indicates a potential upside of 14.03 percent. TEVA stock price is now -7.13% away from the 50-day moving average and -2.91% away from the 200-day moving average. The market capitalization of the company currently stands at $9.73B.

A total of 5 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $10.71 as their price target over the next twelve months.

With the price target enhanced from $7 to $8, UBS Upgraded its rating from Sell to Neutral for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA).

In other news, Kalif Eliyahu Sharon, EVP, Chief Financial Officer sold 35,125 shares of the company’s stock on Aug 07. The stock was sold for $341,889 at an average price of $9.73. Upon completion of the transaction, the EVP, Chief Financial Officer now directly owns 99,162 shares in the company, valued at $0.86 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 04, Chief Accounting Officer Weiss Amir sold 1,981 shares of the business’s stock. A total of $19,658 was realized by selling the stock at an average price of $9.92. This leaves the insider owning 42,442 shares of the company worth $0.37 million. Insiders disposed of 77,421 shares of company stock worth roughly $0.67 million over the past 1 year. A total of 0.01% of the company’s stock is owned by insiders.

Friday’s opening bell rang with an opening price of $8.81 for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA). During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $7.09 and a high of $11.44. As of last week, the company has a debt-to-equity ratio of 2.93, a current ratio of 1.00, and a quick ratio of 0.65. The fifty day moving average price for TEVA is $9.32 and a two-hundred day moving average price translates $8.93 for the stock.

The latest earnings results from Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.56, beating analysts’ expectations of $0.52 by 0.04. This compares to $0.05 EPS in the same period last year. The net profit margin was -14.43% and return on equity was -28.17% for TEVA. The company reported revenue of $3.85 billion for the quarter, compared to $3.6 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.09 percent. For the current quarter, analysts expect TEVA to generate $3.72B in revenue.

Related Posts